Home / Mazdutide 5MG 10MG
  • Mazdutide 5MG 10MG
  • Mazdutide 5MG 10MG

Mazdutide 5MG 10MG

The peptide will be provided as lyophilized powder to ensure maximum stability.
Mazdutide is a new - generation long - acting dual - target agonist that acts on GLP - 1R and GCGR. By activating GLP - 1R, it stimulates insulin secretion in a glucose - dependent way, inhibits glucagon secretion, slows gastric emptying, and suppresses appetite, effectively controlling blood glucose levels. Meanwhile, the activation of GCGR by Mazdutide enhances lipolysis, increases energy expenditure, reduces liver fat accumulation, and exerts significant weight - loss effects. In addition, Mazdutide shows positive effects in improving hyperuricemia, regulating blood pressure, and providing cardiovascular protection. With its multiple - target - acting mechanism, Mazdutide offers a highly potential therapeutic choice for patients with type 2 diabetes, obesity, and other metabolic diseases.
$180
$225
Quantity
ADD TO CART
BUY IT NOW
  • Detail

    Mazdutide (IBI-362) 10mg — Dual GLP-1R/GCGR Agonist for Research

    Mazdutide (IBI-362 / LY-3305677 / OXM-3) is a long-acting synthetic oxyntomodulin (OXM) analog and a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Engineered on the OXM scaffold, it mimics and enhances the dual-receptor activity of the endogenous intestinal hormone while extending its half-life from minutes to days through fatty-acid acylation.

    Structurally, Mazdutide is a 40-amino-acid peptide backbone carrying an AEEA-AEEA-γ-Glu linker conjugated to a C20 fatty diacid (eicosanedioic acid) side chain at Lys20, with an Aib substitution at position 2 and a C-terminal amidation. This design provides DPP-4 resistance, albumin binding, and a prolonged circulation time suitable for once-weekly research dosing schedules.

    Each vial contains 10mg of Mazdutide, supplied as a sterile white to off-white lyophilized (freeze-dried) powder.

    ▎Product Specifications

    Product Name Mazdutide
    Synonyms IBI-362; LY-3305677; OXM-3
    Amino Acid Sequence His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys20(AEEA-AEEA-γ-Glu-Eicosanedioic acid)-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
    Key Modifications Aib2 substitution; Lys20-conjugated C20 fatty diacid via AEEA-AEEA-γ-Glu linker; C-terminal amidation
    Molecular Formula C210H322N46O67
    Molecular Weight 4563.06 g/mol
    CAS Number 2259884-03-0
    PubChem CID 167312357
    Appearance White to off-white solid powder
    Solubility Soluble in water (approx. 22 mg/mL) and PBS (pH 7.2)
    Quantity 10mg / vial
    Purity ≥99% as determined by HPLC
    Certificate of Analysis COA available upon request / downloadable

    ▎Research Highlights

    • Balanced Dual GLP-1R / GCGR Agonism: Mazdutide activates both the GLP-1 receptor (appetite suppression, glucose-dependent insulin secretion) and the glucagon receptor (energy expenditure, hepatic lipid oxidation) — a dual mechanism that distinguishes it from single-target GLP-1 receptor agonists.
    • Nanomolar Potency: Published in vitro data report an EC50 of approximately 0.08 nM at human GLP-1R and 0.45 nM at human GCGR (cAMP accumulation assays), with no significant activity at GIPR.
    • Long-Acting Design: Fatty-acid acylation extends the half-life to roughly 72 hours in reported studies, supporting once-weekly dosing schedules in research protocols.
    • Oxyntomodulin-Based Scaffold: Built on the native OXM dual-agonist framework, Mazdutide is a key reference compound for investigating incretin/glucagon co-agonist pharmacology.
    • Broad Metabolic Research Interest: Investigated in preclinical and clinical studies of obesity, type 2 diabetes, hepatic steatosis, and related cardiometabolic endpoints.

    ▎Mechanism of Action (Summary)

    Mazdutide exerts its effects through coordinated activation of two G protein-coupled receptors:

    • GLP-1R activation: promotes glucose-dependent insulin secretion in pancreatic β cells and activates central appetite-suppression pathways;
    • GCGR activation: stimulates hepatic lipid oxidation and energy expenditure, contributing to body weight and liver fat reduction;
    • Balanced signaling: the designed GLP-1/GCGR activity ratio offsets the hyperglycemic potential of glucagon signaling with GLP-1-mediated insulinotropic effects;
    • Half-life extension: albumin binding via the fatty diacid side chain slows renal clearance and enzymatic degradation.

    ▎Storage & Handling

    Lyophilized Powder Store at −20°C, sealed, dry and protected from light; for long-term storage, −80°C or nitrogen atmosphere is recommended.
    Reconstitution Dissolve in sterile water or PBS; gentle agitation is recommended. Avoid vigorous vortexing for reconstituting lipidated peptides.
    After Reconstitution Store solutions at 2–8°C for short-term use; for longer storage, aliquot and keep at −20°C or −80°C. Avoid repeated freeze-thaw cycles.
    Handling Notes Allow vial to reach room temperature before opening to reduce moisture uptake. Handle with standard laboratory protective equipment.

    Quality Assurance

    Every batch of Mazdutide is verified by HPLC for purity and Mass Spectrometry for molecular weight confirmation. A Certificate of Analysis (COA) is provided with each order, and independent third-party testing reports are available upon request.

    Important Notice — Research Use Only

    All product information on this page is provided solely for informational and educational purposes. The products offered are intended exclusively for laboratory and in vitro research. They are not pharmaceuticals, have not been approved by the U.S. Food and Drug Administration (FDA), and are not intended to diagnose, prevent, treat, or cure any medical condition. These products must not be administered to humans or animals. By purchasing, you confirm that you are a qualified researcher and that the product will be used only for lawful research purposes.

  • Customer Reviews
    No comments
BACK